Metabolic profiling and cytochrome P450 reaction phenotyping of medroxyprogesterone acetate

Drug Metabolism and Disposition

Volumn 36, Issue 11, 2008, Pages 2292-2298

  Zhang, Jiang Wei ^a,b   Liu, Yong ^a   Zhao, Jiu Yang ^c   Wang, Li Ming ^c   Ge, Guang Bo ^a,b   Gao, Yang ^c   Li, Wei ^a,b   Liu, Hong Tao ^a,b   Liu, Hui Xin ^a,b   Zhang, Yan Yan ^a,b   Sun, Jie ^c   Yang, Ling ^a  

^a DALIAN INSTITUTE OF CHEMICAL PHYSICS   (China)

^b UNIVERSITY OF CHINESE ACADEMY OF SCIENCES   (China)

^c DALIAN MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CLOMETHIAZOLE; CYTOCHROME P450 3A4; FURAFYLLINE; KETOCONAZOLE; MEDROXYPROGESTERONE ACETATE; METHOXSALEN; MONTELUKAST; OMEPRAZOLE; QUINIDINE; SULFAPHENAZOLE; THIOTEPA;

ADULT; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; HUMAN; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; LIVER MICROSOME METABOLISM; MALE; MASS SPECTROMETER; PHENOTYPE; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; STEROID METABOLISM;

ADULT; ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; GENE EXPRESSION PROFILING; HUMANS; MALE; MEDROXYPROGESTERONE 17-ACETATE; MIDDLE AGED; PHENOTYPE; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SWINE; SWINE, MINIATURE;

RATTUS;

EID: 54349113784     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.108.022525     Document Type: Article

References (40)

1. Adis International Ltd. (2003) CBP 1011: Colirest, Hematrol. Drugs R D 4:241-242.
2. Anzenbacher P, Soucek P, Anzenbacherová E, Gut I, Hrubý K, Svoboda Z, and Květina J (1998) Presence and activity of cytochrome P450 isoforms in minipig liver microsomes: comparison with human liver samples. Drug Metab Dispos 26:56-59.
3. Bjornsson TD, Callaghan JT, Einolf HJ, Fischer V, Gan L, Grimm S, Kao J, King SP, Miwa G, Ni L, et al. (2003) The conduct of in vitro and in vivo drug-drug interaction studies: a PhRMA perspective. J Clin Pharmacol 43:443-469.
4. Bonny AE, Britto MT, Huang B, Succop P, and Slap GB (2004) Weight gain, adiposity, and eating behaviors among adolescent females on depot medroxyprogesterone acetate (DMPA). J Pediatr Adolesc Gynecol 17:109-115.
5. Castegnaro E and Sala G (1962) Isolation and identification of 6beta,17alpha,21-trihydroxy-6alpha-methyl-delta4-pregnene-3, 20-dione (21-acetate) from the urine of human subjects treated with 6alpha-methyl- 17alpha-acetoxyprogesterone. J Endocrinol 24:445-452.
6. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, Rodabough RJ, Gilligan MA, Cyr MG, Thomson CA, et al. (2003) Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA 289:3243-3253.
7. Chotnopparatpattara P and Taneepanichskul S (2000) Use of depot medroxyprogesterone acetate in Thai adolescents. Contraception 62:137-140.
8. Cromer BA, Stager M, Bonny A, Lazebnik R, Rome E, Ziegler J, and Debanne SM (2004) Depot medroxyprogesterone acetate, oral contraceptives and bone mineral density in a cohort of adolescent girls. J Adolesc Health 35:434-441.
9. Dollery C (1998) Medroxyprogesterone acetate, in Therapeutic Drugs, 2nd ed (Dollery C ed) pp M17-M21, Churchill Livingstone, Edinburgh, UK.
10. Etienne MC, Milano G, Frenay M, Renee N, Francois E, Thyss A, Schneider M, and Namer M (1992) Pharmacokinetics and pharmacodynamics of medroxyprogesterone acetate in advanced breast cancer patients. J Clin Oncol 10:1176-1182.
11. Fang XG, Zhang QM, Ling DK, and Song YW (1986) [Studies on the purity of Chinese megestrol acetate: separation and identification of epimeric isomers of 6-hydroxy-6-methyl-17 alpha-acetoxy-progesterone]. Yao Xue Xue Bao 21:613-617.
12. Fotherby K (1996) Bioavailability of orally administered sex steroids used in oral contraception and hormone replacement therapy. Contraception 54:59-69.
13. Fukushima DK, Levin J, Liang JS, and Smulowitz M (1979) Isolation and partial synthesis of a new metabolite of medroxyprogesterone acetate. Steroids 34:57-72.
14. Ghatge RP, Jacobsen BM, Schittone SA, and Horwitz KB (2005) The progestational and androgenic properties of medroxyprogesterone acetate: gene regulatory overlap with dihydrotestosterone in breast cancer cells. Breast Cancer Res 7:R1036-R1050.
15. Guo F, Feng H, Wang Y, Zhang C, and Li Y (2006) Characterization of related impurities in megestrol acetate. J Pharm Biomed Anal 41:1418-1422.
16. Helmreich ML and Huseby RA (1962) Identification of a 6,21-dihydroxylated metabolite of medroxyprogesterone acetate in human urine. J Clin Endocrinol Metab 22:1018-1032.
17. Hersh AL, Stefanick ML, and Stafford RS (2004) National use of postmenopausal hormone therapy: annual trends and response to recent evidence. JAMA 291:47-53.
18. Ko JW, Sukhova N, Thacker D, Chen P, and Flockhart DA (1997) Evaluation of omeprazole and lansoprazole as inhibitors of cytochrome P450 isoforms. Drug Metab Dispos 25:853-862.
19. Kobayashi K, Mimura N, Fujii H, Minami H, Sasaki Y, Shimada N, and Chiba K (2000) Role of human cytochrome P450 3A4 in metabolism of medroxyprogesterone acetate. Clin Cancer Res 6:3297-3303.
20. Kobayashi K, Urashima K, Shimada N, and Chiba K (2003) Selectivities of human cytochrome P450 inhibitors toward rat P450 isoforms: study with cDNA-expressed systems of the rat. Drug Metab Dispos 31:833-836.
21. Koenigs LL, Peter RM, Thompson SJ, Rettie AE, and Trager WF (1997) Mechanism-based inactivation of human liver cytochrome P450 2A6 by 8-methoxypsoralen. Drug Metab Dispos 25:1407-1415.
22. Krauser JA, Voehler M, Tseng LH, Schefer AB, Godejohann M, and Guengerich FP (2004) Testosterone 1 beta-hydroxylation by human cytochrome P450 3A4. Eur J Biochem 271:3962-3969.
23. Li J, Liu Y, Zhang JW, Wei H, and Yang L (2006) Characterization of hepatic drug-metabolizing activities of Bama miniature pigs (Sus scrofa domestica): comparison with human enzyme analogs. Comp Med 56:286-290.
24. Lobo RA (1999) Progestogen metabolism. J Reprod Med 44:148-152.
25. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the folin phenol reagent. J Biol Chem 193:265-275.
26. McCamish M, Rossi E, De Pascale A, Negrini P, and Frigerio A (1980) The in vitro metabolism of medroxyprogesterone acetate, in Recent Developments in Mass Spectrometry in Biochemistry and Medicine (Frigerio A ed) pp 243-251, Elsevier, Amsterdam, The Netherlands.
27. Mimura N, Kobayashi K, Nakamura Y, Shimada N, Hosokawa M, and Chiba K (2003) Metabolism of medroxyprogesterone acetate (MPA) via CYP enzymes in vitro and effect of MPA on bleeding time in female rats in dependence on CYP activity in vivo. Life Sci 73:3201-3212.
28. Omura T and Sato R (1964) The carbon monoxide-binding pigment of liver microsomes: I. Evidence for its hemoprotein nature. J Biol Chem 239:2370-2385.
29. Otto C, Fuchs I, Altmann H, Klewer M, Walter A, Prelle K, Vonk R, and Fritzemeier KH (2008) Comparative analysis of the uterine and mammary gland effects of drospirenone and medroxyprogesterone acetate. Endocrinology 149:3952-3959.
30. Rae JM, Soukhova NV, Flockhart DA, and Desta Z (2002) Triethylenethiophosphoramide is a specific inhibitor of cytochrome P450 2B6: implications for cyclophosphamide metabolism. Drug Metab Dispos 30:525-530.
31. Ratchanon S and Taneepanichskul S (2000) Depot medroxyprogesterone acetate and basal serum prolactin levels in lactating women. Obstet Gynecol 96:926-928.
32. Rossouw JE, Anderson GL, Prentice RL, LaCroix AZ, Kooperberg C, Stefanick ML, Jackson RD, Beresford SA, Howard BV, Johnson KC, et al. (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 288:321-333.
33. Sesardic D, Boobis AR, Murray BP, Murray S, Segura J, de la Torre R, and Davies DS (1990) Furafylline is a potent and selective inhibitor of cytochrome P450IA2 in man. Br J Clin Pharmacol 29:651-663.
34. Siddique YH, Ara G, Beg T, and Afzal M (2006) Genotoxic potential of medroxyprogesterone acetate in cultured human peripheral blood lymphocytes. Life Sci 80:212-218.
35. Singh M (2007) Progestins and neuroprotection: are all progestins created equal? Minerva Endocrinol 32:95-102.
36. Sturm G, Häberlein H, Bauer T, Plaum T, and Stalker DJ (1991) Mass spectrometric and high-performance liquid chromatographic studies of medroxyprogesterone acetate metabolites in human plasma. J Chromatogr 562:351-362.
37. Walsky RL, Obach RS, Gaman EA, Gleeson JP, and Proctor WR (2005) Selective inhibition of human cytochrome P4502C8 by montelukast. Drug Metab Dispos 33:413-418.
38. Wood CE, Register TC, Lees CJ, Chen H, Kimrey S, and Cline JM (2007) Effects of estradiol with micronized progesterone or medroxyprogesterone acetate on risk markers for breast cancer in postmenopausal monkeys. Breast Cancer Res Treat 101:125-134.
39. Zhang JW, Liu Y, Cheng J, Li W, Ma H, Liu HT, Sun J, Wang LM, He YQ, Wang Y, et al. (2007) Inhibition of human liver cytochrome P450 by star fruit juice. J Pharm Pharm Sci 10:496-503.
40. Zhang JW, Liu Y, Li W, Hao DC, and Yang L (2006) Inhibitory effect of medroxyprogesterone acetate on human liver cytochrome P450 enzymes. Eur J Clin Pharmacol 62:497-502.